Business Context and Reporting Period
This Form 8-K reports on the Annual Meeting of Stockholders held by Cerulean Pharma Inc. on June 22, 2016. The filing details the outcomes of shareholder votes regarding director elections and the ratification of the independent auditor. Note: The request metadata references "Dare Bioscience, Inc.", but the filing text explicitly identifies the registrant as Cerulean Pharma Inc.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on corporate governance matters and does not contain financial performance data.
Material Changes
No material financial changes are reported in this filing. The document serves to disclose the results of the shareholder vote rather than operational or financial shifts.
Guidance, Outlook, and Management Commentary
The filing contains no guidance, outlook, or management commentary regarding future business prospects. It strictly reports the procedural results of the annual meeting.
Important Facts for Investors to Verify
- Director Elections: Shareholders elected Alan L. Crane, David R. Parkinson, and David R. Walt as Class II directors to serve until the 2019 Annual Meeting.
- Voting Results:
- Alan L. Crane: 15,018,639 votes for; 1,543,410 abstaining.
- David R. Parkinson: 14,238,518 votes for; 2,323,531 abstaining.
- David R. Walt: 16,373,058 votes for; 188,991 abstaining.
- Auditor Ratification: Shareholders ratified the appointment of Deloitte & Touche LLP as the independent registered public accounting firm with 20,522,808 votes for and 60,143 votes against.
- Broker Non-Votes: There were 4,110,413 broker non-votes recorded for the director elections.